NONMEM Users Network Archive

Hosted by Cognigen

Quantitative pharmacology modelling position available at LEO Pharma A/S, Denmark

From: Stine Timmermann Ottesen <NTMDK>
Date: Wed, 25 Apr 2018 08:13:55 +0000

We are pleased to announce an open modelling position at the department of =
Clinical Pharmacology, LEO Pharma, Denmark.

Population Pharmacokineticist to Clinical Pharmacology

Can you take on the role as LEO´s new specialist in quantitative pharmaco=
If you have a solid background within population pharmacokinetics you now h=
ave the opportunity to take on the challenge and become LEO Pharma's new sp=
ecialist within your field of expertise. You will join a team of experience=
d and highly skilled scientists committed to understand the mechanisms behi=
nd skin diseases and how our candidate drugs influence these mechanisms. We=
 have just launched an extremely ambitious 2025 strategy and Clinical Pharm=
acology is an important part of that strategy. As specialist in population =
pharmacokinetics and quantitative pharmacology you will be a key driver on =
this journey. You can look forward to joining LEO in one of the most exciti=
ng times in our history.

Your job
You will join an international market leader within dermatology with focus =
on inflammatory skin diseases. We have a rich project portfolio that covers=
 topical, systemic and mAb treatment solutions. Your overall focus will be =
to further build and implement population pharmacokinetics and PK/PD modell=
ing in all of our clinical projects. Your primary tasks will be to:
*Apply population PK & PK/PD modelling and simulation to support our clinic=
al projects
*Help optimize clinical trial protocols/conduct in particular clinical phar=
macology studies
*Deliver required documentation for authority submissions
*Represent our discipline at authority and external KOL interactions
A vital part of the job is also to keep yourself updated with new developme=
nts in the field of population pharmacokinetics and quantitative pharmacolo=
gy, including relevant regulatory legislation, guidelines and submission pr=
inciples. It is important to keep appraised with the literature and ensure =
continued learning.

Your profile
You have worked within the area of population pharmacokinetics and quantita=
tive pharmacology. It is an advantage if you have experience from authority=
 interactions and clinical trial design of typical clinical pharmacology st=
udies, and if you have published in peer-reviewed. You must be able to comm=
unicate complex information to colleagues across the LEO organisation and t=
o external stakeholders. You thrive on creating results via constructive co=

About the Clinical Pharmacology department
You will join a well-functioning team of 6 colleagues. We are responsible f=
or PK, PK/PD, clinical pharmacology trials, biomarker assessment and mode o=
f action understanding of our drugs in all phases of clinical development. =
We are part of the Medical Science and Safety area, which is a multifunctio=
nal function that embraces several aspects regarding clinical studies, desc=
riptive characterisation and biological understanding of the drug action in=
 human beings.

How to apply
To learn more about this exciting opportunity, please visit http://www.leo-= Look for the job advert and submit your =
application online.
We look forward to receiving your application.

About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to=
 patients in more than 100 countries globally, LEO Pharma supports people i=
n managing their skin conditions.
Founded in 1908 and owned by the LEO Foundation, the healthcare company has=
 devoted decades of research and development to delivering products and sol=
utions to people with skin conditions.
LEO Pharma is headquartered in Denmark and employs around 4,800 people worl=
For more information, visit

This e-mail, inclusive of attachments, is intended for the person(s) stated=
 above and may contain confidential information. Unauthorised reading, disc=
losure, copying, distribution or use of this information may violate rights=
 to proprietary information. If you are not an intended recipient, please r=
eturn this e-mail to the sender and delete your copy. Thank you.

Received on Wed Apr 25 2018 - 04:13:55 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: